Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1983;22(3):239-42.

[Our experience with the clinical trial of postinor--an oral hormonal preparation for postcoital contraception]

[Article in Bulgarian]
  • PMID: 6362451
Clinical Trial

[Our experience with the clinical trial of postinor--an oral hormonal preparation for postcoital contraception]

[Article in Bulgarian]
D Vasilev et al. Akush Ginekol (Sofiia). 1983.

Abstract

PIP: Postcoital contraception aims at the avoidance of unwanted pregnancy in women who have a regimen of rare or accidental sexual contacts. For the 1st time in Bulgaria, the authors examined clinically an oral postcoital preparation, Postinor, which originated in Hungary. Each tablet contains 0.75 mcg of d-norgestrel. The observation included 49 volunteers, ages 19-38, with proven fertility. The preparations were given during the course of 150 menstrual cycles. 1 women became pregnant as a result of improper dosage/multiple contacts during incomplete hormonal protection. There were 3 cases of bleeding (6.1%) and 1 required estrogen correction. The authors found that the best administration regimen was 1 tablet, with the exception of 2 tablets/week. The authors suggest that Postinor could be successfully combined with the rhythm method of Ogion-Knaus. They recommend it for daily contraceptive practice. (author's modified)

PubMed Disclaimer